News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
513,957 Results
Type
Article (21603)
Company Profile (91)
Press Release (492263)
Section
Business (154571)
Career Advice (763)
Deals (28209)
Drug Delivery (78)
Drug Development (63159)
Employer Resources (84)
FDA (14179)
Job Trends (11050)
News (265815)
Policy (25179)
Tag
Academia (1282)
Alliances (38200)
Alzheimer's disease (858)
Approvals (14121)
Artificial intelligence (84)
Bankruptcy (225)
Best Places to Work (8978)
Biosimilars (67)
Breast cancer (70)
Cancer (736)
Cardiovascular disease (61)
Career advice (654)
Cell therapy (179)
Clinical research (51028)
Collaboration (275)
Compensation (109)
COVID-19 (1612)
C-suite (60)
Data (761)
Diabetes (115)
Diagnostics (4671)
Earnings (66777)
Employer resources (69)
Events (83816)
Executive appointments (194)
FDA (14572)
Funding (206)
Gene therapy (123)
GLP-1 (429)
Government (3185)
Healthcare (12681)
Infectious disease (1657)
Inflammatory bowel disease (76)
Interviews (108)
IPO (13062)
Job creations (2354)
Job search strategy (582)
Layoffs (273)
Legal (5170)
Lung cancer (133)
Manufacturing (152)
Medical device (11314)
Medtech (11318)
Mergers & acquisitions (15220)
Metabolic disorders (280)
Neuroscience (1040)
NextGen Class of 2024 (4175)
Non-profit (1876)
Northern California (978)
Obesity (163)
Opinion (129)
Patents (71)
People (40003)
Phase I (15232)
Phase II (22378)
Phase III (17674)
Pipeline (194)
Postmarket research (1804)
Preclinical (6019)
Press Release (67)
Radiopharmaceuticals (184)
Rare diseases (134)
Real estate (4176)
Regulatory (17778)
Research institute (1244)
Resumes & cover letters (97)
Southern California (881)
Startups (2460)
United States (9301)
Vaccines (349)
Weight loss (125)
Date
Today (143)
Last 7 days (708)
Last 30 days (2397)
Last 365 days (29058)
2024 (24615)
2023 (32664)
2022 (42650)
2021 (45899)
2020 (43655)
2019 (35133)
2018 (26697)
2017 (26774)
2016 (25037)
2015 (29788)
2014 (21985)
2013 (17957)
2012 (19755)
2011 (20541)
2010 (18211)
Location
Africa (439)
Arizona (95)
Asia (31632)
Australia (5094)
California (2159)
Canada (905)
China (182)
Colorado (99)
Connecticut (100)
Europe (67982)
Florida (312)
Georgia (81)
Illinois (202)
Indiana (153)
Kansas (78)
Maryland (442)
Massachusetts (1743)
Michigan (147)
Minnesota (179)
New Jersey (734)
New York (689)
North Carolina (525)
Northern California (978)
Ohio (104)
Pennsylvania (590)
South America (785)
Southern California (881)
Texas (287)
Washington State (275)
513,957 Results for "janssen pharmaceutica products l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (“Janssen PMP”) are pleased to announce a significant expansion to their existing Exclusive Evaluation and Option Agreement
September 6, 2023
·
9 min read
MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”), and JANSSEN PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
May 23, 2023
·
7 min read
Business
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
January 8, 2024
·
2 min read
Business
Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration
Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the “Second Interim Award”) from the arbitral tribunal (the “Tribunal”) in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V.
April 25, 2023
·
4 min read
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
April 17, 2024
·
3 min read
Business
Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery
Odyssey Therapeutics, Inc. announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and ooptimize small molecule medicines against select therapeutic targets.
April 4, 2024
·
2 min read
Pharm Country
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
LianBio announced that partner Nanobiotix has entered into a license agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.
July 18, 2023
·
5 min read
Policy
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. (“Janssen”), a subsidiary of Johnson & Johnson.
April 19, 2022
·
4 min read
Press Releases
Johnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research
September 26, 2024
·
5 min read
Business
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen).
January 5, 2024
·
3 min read
1 of 51,396
Next
